Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat;Influencia del rofecoxib en la carcinogénesis cólica perianastomótica inducida en ratas

Revista Espanola de Enfermedades Digestivas

Volumn 97, Issue 6, 2005, Pages 405-415

  Noguera Aguilar, José Francisco ^a   Amengual Antich, I ^b   Moron Canis J M ^c   Plaza Martinez A ^d   Martinez Corcoles J A ^c   Tortajada Collado, C ^c   Pujol Tugores, J J ^a  

^a HOSPITAL SON LLÀTZER   (Spain)

^b HOSPITAL DE MANACOR   (Spain)

^c HOSPITAL SON DURETA   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

Adenocarcinoma; Colorectal cancer; Cyclooxigenase; Rat; Rofecoxib

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL CARCINOGENESIS; COLON ADENOCARCINOMA; COLON ADENOMA; COLON ANASTOMOSIS; COLON CARCINOGENESIS; COLON RESECTION; CONTROLLED STUDY; DIET; DRUG EFFICACY; MALE; NONHUMAN; POSTOPERATIVE COMPLICATION; RAT; RECURRENT CANCER;

EID: 23644456548     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082005000600003     Document Type: Article

References (33)

1. Arnaud JP, Schloegel M, Oilier JC, Adloff M. Colorectal cancer in patients over 80 years of age. Dis Colon Rectum 1991; 34: 896-8.
2. McGregor JR, Galloway DJ, McCulloch P, George WD. Anastomotic suture materials and implantation metastasis: an experimental study. Br J Surg 1989; 76 (4): 331-4.
3. Dominguez F, Riera JR, Junco P, Tojo S, Díaz-Faes M. Influencia en el pronóstico a corto plazo de la sobreexpresion de la proteina p53 en carcinomas colorrectales. Rev Esp Enferm Dig 1994; 86: 796-802.
4. García JC, Cugat E, Angás J, González FJ, Reverter JC, Lacy AM. Cáncer colorrectal: resultados de un protocolo de seguimiento. Cir Esp 1993; 53: 430-3.
5. García JA, Morcillo MA, Vázquez JL, Zaragoza C, Moltó M, Cámara J. Cáncer colorrectal en el anciano. Experiencia de los 5 primeros años en un Servicio de Cirugía de un hospital Comarcal. Cir Esp 1996; 60: 256-7.
6. Lieberman DA. Screening for colorectal cancer. Clin Cornerstone 2002; 4: 1-10.
7. Benamouzig R, Chaussade S. La chimioprevéntion du cancer colorectal. Presse Med 2002; 31: 124-8.
8. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282: 1254-7.
9. Vane JR, Bakle YS, Botting RM. Cyclo-oxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
10. Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, et al. Interpreting the clinical significance of the differential inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2. Rheumatology 1999; 38: 779-88.
11. Lipsky PE, Brooks P, Crofford LJ, DuBois R, Graham D, Simon LS, et al. Unressolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000; 160: 913-20.
12. Williams CS, Mann M, DuBois R. The role of cyclo-oxygenases in inflammation, cancer and development. Oncogene 1999; 18: 7908-16.
13. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110: 1259-2.
14. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 1999; 83: 470-5.
15. Reddy BS, Yoshinobu Y, Lubet R, Steele V, Kelloff G, Paulson S, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60: 293-7.
16. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase -1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 556-2559.
17. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999; 290: 551-60.
18. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations and medications.: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-404.
19. Wargovich MJ, Chen CD, Harris C. Inhibition of aberrant crypt growth by nonsteroidal anti-inflammatory agents an differentiation agents in the rat colon. Int J Cancer 1995; 60: 515-9.
20. Rao CV, Rivenson A, Simi B. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-72.
21. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the Ape gene. Science 1992; 256: 668-70.
22. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000; 60: 5040-4.
23. Oshima m, Murai N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention of intestinal polyposis in the Ape Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61: 1733-40.
24. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566-9.
25. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-12.
26. Halpin RA, Geer LA, Zhang KE, Marks TM, Dean DC, Jones AN, et al. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metab Dispos 2000; 28: 1244-54.
27. Nicoll-Griffith DA, Yergey JA, Trimble LA, Silva JM, Li C, Chauret N, et al. Synthesis, characterization, and activity of metabolites derived from the cyclooxigenase-2 inhibitor rofecoxib (MK-0966, Vioxx). Bioorg Med Chem Lett 2000; 10: 2683-6.
28. Depre M, Ehrich E, Van Hecken A, De Lepeleire I, Dallob A, Wong P, et al. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000; 56: 167-74.
29. Becerra CR, Frenkel EP, Ashfaq R, Gaynor RB. Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study. Int J Cancer 2003; 105: 868-72.
30. Noguera JF, Tortajada C, Moron JM, Plaza A, Amengual I, Pujol JJ. Experimental model for the study of perianastomotic recurrence in colorectal cancer. Rev Esp Enferm Dig 2002; 94: 131-4.
31. Noguera JF, Tortajada C, Zurita M, García JC, Álvarez C, Rial R. Nuevo régimen farmacológico para la inducción de tumores cólicos en ratas. Span J Surg Res 2000; 3: 33-5.
32. Evans JF. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer. Am J Clin Oncol. 2003; 26: 62-5.
33. Taxonera C, Mendoza JL. Colorectal cancer and Coxibs. Rev Esp Enferm Dig 2004; 96: 673-7.